论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Ahn JS, Lin J, Ogawa S, Yuan C, O'Brien T, Le BHC, Bothwell AM, Moon H, Hadjiat Y, Ganapathi A
Received 24 April 2017
Accepted for publication 19 May 2017
Published 18 August 2017 Volume 2017:10 Pages 1963—1972
DOI https://doi.org/10.2147/JPR.S140320
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Minal Joshi
Peer reviewer comments 3
Editor who approved publication: Dr E. Alfonso Romero-Sandoval
Abstract: Treatment
of cancer pain is generally based on the three-step World Health Organization
(WHO) pain relief ladder, which utilizes a sequential approach with drugs of
increasing potency. Goals of pain management include optimization of analgesia,
optimization of activities of daily living, minimization of adverse effects,
and avoidance of aberrant drug taking. In addition, it is recommended that
analgesic regimens are individualized and simplified to help ensure patient
compliance and should provide the least invasive, easiest, and safest route of
opioid administration to ensure adequate analgesia. Buprenorphine and fentanyl
are two opioids available for the relief of moderate-to-severe cancer pain.
Available clinical data regarding the transdermal (TD) formulations of these
opioids and the extent to which they fulfill the recommendations mentioned
earlier are systematically reviewed, with the aim of providing additional
information for oncologists and pain specialists regarding their comparative
use. Due to lack of studies directly comparing TD buprenorphine with TD
fentanyl, data comparing these with other step-3 opioids are also evaluated in
a network fashion.
Keywords: analgesia, cancer pain management, chronic pain/drug therapy, drug
evaluation, pain management, patch analgesics
摘要视频链接:Transdermal buprenorphine and fentanyl patches in cancer pain